Results 181 to 190 of about 6,234,437 (297)

Making sense of low-complexity domains: The 2025 Lasker Basic Science Award. [PDF]

Proc Natl Acad Sci U S A
Kaelin WG.
europepmc   +1 more source

Insights into a long life without cancer: The case of the bowhead whale

Molecular Oncology, EarlyView.
Long‐lived, large‐bodied organisms have evolved powerful anticancer mechanisms that preserve cellular and tissue integrity across extended lifespans. A recent study by Firsanov et al. shows that greater genome stability is a key factor underlying the remarkable longevity and cancer resistance of one such species, the bowhead whale.
Inés Paniagua, Johanna A. Joyce
wiley   +1 more source

From basic science to prevention - the imperative for a convergence science approach for cardio- and cerebrovascular risk reduction in females with diabetes. [PDF]

J Clin Transl Sci
Villablanca AC, Smith BP, Wickman BE, Norman JE, Garrison SL, Nuthikattu S, Milenkovic D, Brown SD.   +7 more
europepmc   +1 more source

The Meniscus: Basic Science and Therapeutic Approaches. [PDF]

J Clin Med
Kuczyński N, Boś J, Białoskórska K, Aleksandrowicz Z, Turoń B, Zabrzyńska M, Bonowicz K, Gagat M.   +7 more
europepmc   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

TNFR2 Agonism: Basic Science and Promising Treatment for Multiple Sclerosis and Related Diseases. [PDF]

Int J Mol Sci
Faustman DL, Davis M, Kuhtreiber WM.
europepmc   +1 more source

Checkpoint blockade and the stem‐like T cell trade‐off

Molecular Oncology, EarlyView.
Stem‐like T cells are key to the success of programmed cell death protein 1 (PD1) blockade, as they sustain long‐term anti‐tumor response by continuously generating effector CD8+ T cells. However, how these cells are maintained in cancer is not fully understood. Hor et al.
Julie M. Mazet, Johanna A. Joyce
wiley   +1 more source

Basic Sciences [PDF]

Journal of Applied Oral Science, 2007
openaire   +2 more sources

Molecular cancer prevention: Intercepting disease

Molecular Oncology, EarlyView.
Oncological practice must evolve, from treating established tumours to proactive cancer interception before clinical manifestation. This will require mechanistic insight into tumour initiation, validated biomarkers of early disease development and redesigned clinical trials, enabling cancer interception to become a core pillar of oncology with the ...
Charlotte Grieco, Tej Pandya, Charles Swanton   +2 more
wiley   +1 more source

Inflammasomes as Potential Therapeutic Targets to Prevent Chronic Active Viral Myocarditis-Translating Basic Science into Clinical Practice. [PDF]

Int J Mol Sci
Przytuła N, Podolec J, Przewłocki T, Podolec P, Kabłak-Ziembicka A.   +4 more
europepmc   +1 more source